Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients

Background. Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection. Everolimus blocks growth factor-mediated transduction signals, preventing organ rejection by a mechanism different than that of calcineurin inhibitors and of mycophenolate mofetil (MMF). Methods. Everolimus (1.5 mg or 3 mg daily) was compared with MMF (2 g daily) in a randomized, multicenter, multinational, 12-month double-blind, double-dummy and 2-year open-label, phase 3 trial in de novo renal allograft recipients (n=588) who also received cyclosporine and corticosteroids as part of a triple immunosuppressive regimen. Results. At 12 months, there were no statistically significant differences between doses of 1.5 and 3 mg/day everolimus and MMF (2 g/day) in incidence of biopsy-proven acute rejection (23.2%, 19.7%, and 24.0%, respectively), graft loss (4.6%, 10.6%, and 9.2%), or death (5.2%, 4.0%, and 2.6%), respectively. Everolimus 1.5 mg/day and MMF were generally equally well tolerated. Both were better tolerated than everolimus 3 mg/day. The incidence of cytomegalovirus infection was significantly lower in patients receiving either 1.5 or 3 mg/day everolimus than in those receiving MMF (5.2% and 7.6% vs. 19.4%, respectively) (P=.001). Conclusions. Everolimus is effective in preventing acute rejection and graft loss in de novo renal allograft recipients receiving a triple immunosuppressive regimen. Prevention of acute rejection, along with reduction in cytomegalovirus infection, addresses two factors known to contribute to chronic rejection in such patients.

[1]  B Nashan,et al.  The role of Certican (everolimus, rad) in the many pathways of chronic rejection. , 2001, Transplantation proceedings.

[2]  R. Oberbauer,et al.  SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10 , 2001, Transplantation.

[3]  V. Emery,et al.  Viral infections and their impact on chronic renal allograft dysfunction. , 2001, Transplantation.

[4]  J M Morales,et al.  Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  J. Kovarik,et al.  Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post‐transplant year: Pharmacokinetics, exposure‐response relationships, and influence on cyclosporine , 2001, Clinical pharmacology and therapeutics.

[6]  M. Manns,et al.  Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. , 2000, British journal of clinical pharmacology.

[7]  A. Nagler,et al.  INCREASED IMPACT OF ACUTE REJECTION ON CHRONIC ALLOGRAFT FAILURE IN RECENT ERA , 2000, Transplantation.

[8]  G. Berry,et al.  Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. , 2000, The Journal of pharmacology and experimental therapeutics.

[9]  P. Halloran,et al.  The use of mycophenolate mofetil in transplant recipients. , 2000, Immunopharmacology.

[10]  G. Berry,et al.  Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and , 2000, Transplantation.

[11]  E. Sullivan,et al.  The impact of acute rejection on chronic rejection: A report of the North American Pediatric Renal Transplant Cooperative Study , 2000, Pediatric transplantation.

[12]  G. Berry,et al.  Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability. , 2000, Transplantation.

[13]  A. Matas,et al.  Features of acute rejection that increase risk for chronic rejection. , 1999, Transplantation.

[14]  G. Berry,et al.  Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment. , 1999, Transplantation.

[15]  G. Berry,et al.  Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  H. Schuurman,et al.  SDZ RAD inhibits cold ischemia-induced vascular remodeling. , 1999, Transplantation proceedings.

[17]  O. Cole,et al.  Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. , 1998, Transplantation proceedings.

[18]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[19]  T. Meerloo,et al.  SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. , 1997, Transplantation.

[20]  Randall G. Lee,et al.  Banff schema for grading liver allograft rejection: An international consensus document , 1997, Hepatology.

[21]  W. Bennett,et al.  Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. , 1996, Transplantation.

[22]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[23]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .